(Q36965612)

17 August 2017

1 reference

title

Pegvisomant in acromegaly: why, when, how. (English)

1 reference

17 August 2017

1

A Colao

1 reference

17 August 2017

18

E Ghigo

1 reference

17 August 2017

11

A Giustina

1 reference

17 August 2017

2

G Arnaldi

1 reference

17 August 2017

7

L De Marinis

1 reference

Systemic steroids in patients with COVID-19: pros and contras, an endocrinological point of view

17 August 2017

12

object named as

S Grottoli

1 reference

17 August 2017

8

E De Menis

1 reference

17 August 2017

Ettore C degli Uberti

6

object named as

E degli Uberti

1 reference

17 August 2017

4

S Cannavò

1 reference

17 August 2017

14

P Maffei

1 reference

17 August 2017

17

R Pivonello

1 reference

17 August 2017

P Beck-Peccoz

3

1 reference

17 August 2017

R Cozzi

5

1 reference

17 August 2017

D Ferone

9

1 reference

17 August 2017

V Gasco

10

1 reference

17 August 2017

G Lombardi

13

1 reference

17 August 2017

E Martino

15

1 reference

17 August 2017

F Minuto

16

1 reference

17 August 2017

publication date

1 September 2007

1 reference

Journal of Endocrinological Investigation

17 August 2017

published in

1 reference

17 August 2017

volume

30

1 reference

17 August 2017

issue

8

1 reference

17 August 2017

page(s)

693-699

1 reference

https://scigraph.springernature.com/pub.10.1007/bf03347452

17 August 2017

exact match

0 references

cites work

Systemic complications of acromegaly: epidemiology, pathogenesis, and management

1 reference

https://api.crossref.org/works/10.1007%2FBF03347452

Medical progress: Acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347452

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347452

A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347452

Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347452

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347452

Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347452

Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347452

Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347452

Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347452

The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347452

Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347452

Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347452

Effects of a growth hormone receptor antagonist on bone markers in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347452

Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347452

Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347452

Predictors and rates of treatment-resistant tumor growth in acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347452

Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347452

Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347452

Somatostatin analogs in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347452

Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347452

Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347452

McCune-Albright syndrome and acromegaly: effects of hypothalamopituitary radiotherapy and/or pegvisomant in somatostatin analog-resistant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347452

Treatment with Growth Hormone Receptor Antagonist in Acromegaly: Effect on Cardiac Structure and Performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347452

Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist pegvisomant

21 January 2018

1 reference

12 December 2020

Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient

1 reference

12 December 2020

Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3.

1 reference

12 December 2020

Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant

1 reference

12 December 2020

Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women

1 reference

12 December 2020

Resistance to somatostatin analogs in acromegaly: an evolving concept?

1 reference

12 December 2020

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03347452

1 reference

17 August 2017

1 reference